With current recommendations aiming to reduce the radial artery occlusion (RAO) incidence < 5% after transradial approach, Nanostent has developed a unique dual artery hemostasis device. The Terry2™ band offers effortless, very comfortable, non-occlusive hemostasis in a shortened period of time.
Initial clinical testing has been performed in Canada and in Mexico and physicians and nurses have been impressed by Terry2™ band performance compared to standard single-artery hemostasis device. To date no case of RAO has been faced and hemostasis has been completed in maximum 2 hours without complication in all patients.
Nanostent will partner with interventional cardiologists and nurses at Institut Universiaire de Cardiologie et de Pneumologie de Québec (IUCPQ) to complete a randomized study to fully demonstrate the clinical benefits of using Terry2™ band. Results will be reported in May 2020.
With more than 200,000 percutaneous diagnostic angiography and interventions performed in Canada annually with > 75% completed by transradial approach, Nanostent is well positioned to launch initial marketing release in Q1 2020. After initial commercialization in Canada, Nanostent plans to launch Terry2™ band in Mexico and Latin-America during Q2 2020.
For more information, contact us
Olivier F. Bertrand